The CABG trial described above is the only study to follow renal function up to 3 months found a nonsignificant trend towards lower incident chronic kidney disease (CKD) 17% vs. 24% [ 34 ▪ ].
← all excerpts
The therapeutic horizon of acute kidney injury in critical care: exploring pathology, promises, pitfalls, and progress.
2
—
—
The sentences
Vasopressin/terlipressin Although individual trials were underpowered or did not reach statistical significance, a meta-analysis ( n = 1453; patients in septic shock) showed a trend for reduced RTT requirement [ 11 ], suggesting an early intrinsic or catecholamine sparing renoprotective window.